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Abstract
Background: Altered metabolism is a hallmark of cancer. However, the role of genomic changes in metabolic
genes driving the tumour metabolic shift remains to be elucidated. Here, we have investigated the genomic
and transcriptomic changes underlying this shift across ten different cancer types.
Results: A systematic pan-cancer analysis of 6538 tumour/normal samples covering ten major cancer types identified a
core metabolic signature of 44 genes that exhibit high frequency somatic copy number gains/amplifications (>20 %
cases) associated with increased mRNA expression (ρ > 0.3, q < 10−3). Prognostic classifiers using these genes were
confirmed in independent datasets for breast and kidney cancers. Interestingly, this signature is strongly associated
with hypoxia, with nine out of ten cancer types showing increased expression and five out of ten cancer types
showing increased gain/amplification of these genes in hypoxic tumours (P≤ 0.01). Further validation in breast and
colorectal cancer cell lines highlighted squalene epoxidase, an oxygen-requiring enzyme in cholesterol biosynthesis, as
a driver of dysregulated metabolism and a key player in maintaining cell survival under hypoxia.
Conclusions: This study reveals somatic genomic alterations underlying a pan-cancer metabolic shift and suggests
genomic adaptation of these genes as a survival mechanism in hypoxic tumours.
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Background
The role of the microenvironment in driving tumour
progression is increasingly recognised. Hypoxia is one of
the key physiological and microenvironmental differences
between tumour and normal tissues; it induces DNA
amplification and damage, whilst reducing repair [1].
Moreover, hypoxia along with acidosis increases clonal
selection, resulting in aggressive cancer phenotypes. A
crucial mechanism underlying such evolution in a highly
dynamic tumour microenvironment is metabolic repro-
gramming of tumour cells [2–5]. Metabolic adaptation is
an emerging hallmark of cancer [6]. It has also been
recognised that altered gene regulatory networks in cancer
drive the activity of metabolic pathways (reviewed in [4]).
Although there are some well-described mutations, e.g. of
IDH1 and IDH2 [7–10], this is not the case for the vast
majority of such genes. Thus, the complex landscape of
oncogenic activity of metabolic pathways is far from
understood. Therefore, there is an urgent need for under-
standing the genetic basis of regulation of metabolic
genes, characterising their role in driving tumour growth
and assessing their potential as new therapeutic targets.
Recent studies have examined transcriptional deregu-
lation in metabolic pathways across different cancers
[11–13], identifying candidate drivers of cancer metabolic
adaptation. Although these studies highlight the molecular
underpinnings of altered metabolism, the mechanisms
driving the metabolic shift and clinical potential of meta-
bolic drivers remain obscure. For instance, changes in
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mRNA abundance can arise from either altered transcrip-
tional machinery or genomic aberrations. Therefore, in
order to elucidate mechanistic insights into the dysregu-
lated metabolism of cancer cells and identify potential
drivers of this hallmark, it is crucial to study genomic
aberrations alongside transcriptional changes. Here, we
hypothesise that metabolic requirements in the hypoxic
tumour microenvironment are driving selection of gen-
omic alterations leading to genetic heterogeneity as well
as transcriptional deregulation. To test this hypothesis
high-resolution genomic and transcriptomic profiles of
metabolic transporters and enzymes in tumour and normal
tissue samples are necessary, as well as associated clinical
annotations. Courtesy of projects such as The Cancer
Genome Atlas (TCGA), the International Cancer Genome
Consortium [14] (ICGC) and Metabric [15], genomic,
transcriptomic, epigenomic and proteomic profiles across
multiple tumour types have been generated in thousands
of well-annotated human cancer samples. Thus, using
these profiles, we conducted a pan-cancer integrated ana-
lysis of 6538 matched genomic and transcriptomic profiles
covering ten tumour types in a comprehensive collection
of 2752 metabolic enzyme and transporter genes. Spe-
cifically, we asked whether (1) somatically acquired
mutations are independent drivers of metabolic shift, (2)
over-expression of metabolic genes [13, 16] is induced by
somatically acquired copy-number alterations, (3) meta-
bolic genes are associated with previously reported cancer
drivers [17–19] and (4) metabolic genes are associated
with tumour hypoxia [20] and (5) are prognostic. We then
evaluated the top-ranked key rate-limiting enzyme SQLE
in a panel of aggressive breast cancers and colorectal
cancer cell lines.
Results
Pan-cancer metabolic landscape and increased
dysregulation in hypoxic tumours
A previously curated list of 2752 metabolic enzyme and
transporter genes extracted from the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database (Additional
file 1 and Additional file 2: Table S1) was considered,
offering coverage of over-expressed metabolic genes in
cancer tissues and association with stemness as well as ag-
gressive breast cancers [13]. To systematically identify
pan-cancer metabolic gene signatures characterising
multi-tissue cancer profiles, genomic (DNA somatic mu-
tations and copy number aberrations) and transcriptomic
(mRNA abundance) data from 6538 samples spanning ten
cancer types [15, 21–29] were analysed (Additional file 1
and Additional file 2: Table S2).
We first asked whether genomic alterations were
globally enriched in metabolic genes. We found no
difference in the mean frequency of somatic copy
number alterations (SCNAs) across all cancers between
the 2752 metabolic genes and other genes (P = 0.85, two-
sided proportion test) and a slight but not significant
decrease in the mean frequency of somatic mutations
(P = 0.06, two-sided proportion test).
Given hypoxia is the main microenvironmental factor
associated with dysregulated metabolism [2–5] and
genomic instability [1, 30], we asked whether genomic
alterations in metabolic genes are associated with
tumour hypoxia. To achieve this, we applied a previously
validated hypoxia signature [20, 31], which we confirmed
to be higher in tumour samples compared with normal
tissues for the cancer types considered here (Additional
file 1: Figure S1a). We observed an increase in genomic
alterations in metabolic genes in hypoxic tumours, with
a varying degree of significance depending on the type of
alteration and cancer type. Specifically, tumour hypoxia
was correlated with the extent of SCNAs in metabolic
genes in up to seven of the ten cancer types (P < 0.05,
one-sided Wilcoxon test; Additional file 1: Figure S1b, c)
and with the extent of somatic mutations in three of the
ten cancer types (Additional file 1: Figure S1d). This
agrees with recent reports of hypoxia-driven transient
SCNAs in cancer [32]. We tested this further by looking
at the acquisition of early genomic aberrations in a
stable diploid human cancer cell line model in vivo,
complementing the results obtained from the cancer
samples and from models with a higher background of
genetic instability. After treatment with the antiangio-
genic drug bevacizumab, inducing hypoxia (Additional
file 1: Figure S2a), we observed SCNA events exclusive
to the treatment group (Additional file 1: Figure S2b, c).
Considering the chromosomal stability of this cell line,
this represents a significant genetic change. Interestingly,
the main alteration was in the copy number of chromo-
some 12, which is significantly enriched for metabolism
genes compared with other chromosomes (Poverlap = 0.03,
hypergeometric test; Additional file 1: Figure S2d). Given
the variety of cancer types and experimental systems
considered, the above results taken together suggest that
genomic alterations in metabolic pathways, and particu-
larly in SCNAs, act as a conserved selective pressure in
hypoxic tumours.
We then asked if we could identify specific SCNA
events linked with over-expression across cancer types;
if identified, such events would constitute candidate
metabolism drivers. This is based on the commonly
accepted hypothesis that a strong correlation between
DNA and mRNA levels is indicative of a gain of function.
Specifically, we selected the top 10 % over-expressed genes
with respect to normal tissue, across all tumour types
(log2 fold change >0.5; Additional file 1 and Additional
file 2: Table S3), and further limited this group to
those which were recurrently gained or amplified (puta-
tive) in at least 20 % of samples in each cohort (Additional
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file 1: Figure S3). Next, we performed a pan-cancer correl-
ation analysis which revealed a total of 277 metabolic
genes exhibiting positive correlation across different
cancer types (Spearman’s ρ > 0.3, q < 10−3; Additional file 1
and Additional file 2: Tables S4 and S5).
Interestingly, the frequency of these candidate meta-
bolic drivers varied remarkably between cancers, from
six genes (kidney renal cell carcinoma (KIRC)) to 143
genes (ovarian cancer (OV)) (Additional file 1: Figure
S4a). The number of candidate metabolic drivers was
significantly higher than expected by chance in breast
carcinoma (BRCA), colorectal adenocarcinoma (COAD-
READ), glioblastoma multiforme (GBM) and OV (P < 10−4;
using 10,000 randomly chosen non-metabolic gene sets; see
the “Permutation analysis” section in the “Methods”). To
identify metabolic processes essential to multiple tumours,
we prioritised 44 core metabolic drivers with significantly
correlated DNA and mRNA changes in cancer samples
(Spearman’s ρ > 0.3, q < 10−3) in at least three of the ten
tumour types (Fig. 1a; Additional file 1: Figure S4b, c;
Additional file 1; Additional file 2: Table S6). The top candi-
date metabolic drivers were PYCRL, ALG3 and NUDT1,
A
C
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Fig. 1 Candidate core pan-cancer drivers of metabolic dysregulation and hypoxia association. a For each candidate driver, the cumulative bar
chart shows the inclusion frequencies representing the number of cancer types whereby mRNA and copy number profiles were correlated. The
inclusion criterion was arbitrarily set to a minimum of three cancers. The heat map shows the extent of genomic aberrations for the selected
candidate drivers as well as the corresponding cancer types. The intensity indicates the fraction of the cohort in which a given gene has either a
gain or amplification. The rows (tumour types) were ordered using hierarchical clustering. b The distribution of core candidate metabolic drivers
in statistically enriched compartments of metabolic pathways. The number in each segment indicates the metabolic genes present in that compartment.
The dashed arcs (with numbers) indicate the number of genes shared between the compartments (Additional file 1 and Additional file 2: Table S7).
c Cancer-wise mRNA correlations (Spearman’s correlation coefficients) of core metabolic signature (44 genes, Sig. group) and hypoxia score and
compared with the correlations between non-selected metabolic genes (Other) and hypoxia score. For each cancer type, the distribution of both sets
of correlations was compared using a one-sided Wilcoxon test and the P values are displayed. Box plots are sorted (high on the left to low on the right)
by the median correlation coefficient in the signature (Sig.) set of scores. To avoid bias, three genes common to the metabolism signature and hypoxia
signature and another up to 17 genes (depending upon the cancer type) common to the non-selected metabolic group and hypoxia signature were
removed. BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, LUAD lung adenocarcinoma, COADREAD colorectal adenocarcinoma,
GBM glioblastoma multiforme, UCEC uterine corpus endometrial carcinoma, KIRC Kidney renal clear cell carcinoma, LUSC lung squamous cell carcinoma,
HNSC head and neck squamous cell carcinoma, OV Ovarian serous cystadenocarcinoma
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which were correlated in at least seven of the ten tumour
types. The list also contained TYMS, a well-known chemo-
therapeutic target [33], and another five genes (GAPDH,
PYCR1, TPI1, TSTA3 and TTYH3) for which inhibition of
expression has been previously shown to reduce cell viabil-
ity in in vitro and in vivo functional genomics screens [13].
These 44 genes were significantly enriched in five overlap-
ping metabolic processes (Fig. 1b; Additional file 1;
Additional file 2: Table S7), including pyrimidine
metabolism (six genes, q = 1.97 × 10−4), drug metabolism
(six genes, q = 1.97 × 10−4) and purine metabolism (five
genes, q = 0.039).
We then asked if there was an increased association of
these 44 genes with hypoxia relative to other metabolic
genes. Remarkably, nine of the ten cancer types showed
significantly greater positive correlation between the
expression of the 44 core metabolic drivers and the
hypoxia signature compared with the remainder of the
metabolic genes (Fig. 1c; P ≤ 0.01, one-sided Wilcoxon
test). A similar pattern was maintained in five of the ten
cancer types when considering SCNA profiles (Additional
file 1: Figure S5a). The association between hypoxia and
these 44 genes was also reflected in a significantly elevated
fraction of copy number gains for these genes in patients
with higher hypoxia in four of the ten cancer types
(Additional file 1: Figure S5b; P < 0.05, one-sided
Wilcoxon test). Conversely, hypoxia was not associated
with the extent of somatic mutations in these 44 genes
(Additional file 1: Figures S5c). This reflects the lower
frequency of somatic mutations in these genes, with an
overall mutation rate ranging from 0.056 % (PYCRL) to
2.212 % for (ABCC5) (Additional file 1 and Additional file
2: Table S8a). Evaluation of all metabolic genes revealed
only 12 out of 2752 genes somatically mutated at a mean
frequency of >5 % (Additional file 1 and Additional file 2:
Table S8b). These results support the hypothesis that a
core group of metabolic genes are preferentially selected
through genomic gains/amplifications, with rare excep-
tions such as IDH1/2 [7–10]. Equivalent analysis focussing
on down-regulated genes with genomic losses resulted in
only three recurrent candidates of metabolism (Additional
file 1 and Additional file 2: Table S9).
In summary, we identified a core set of 44 metabolic
genes which are over-expressed in tumour samples
through genomic gains/amplification, exhibit low rates
of somatic mutations and demonstrate correlation with
tumour hypoxia.
Association of candidate metabolic drivers with
previously reported cancer drivers
We next asked whether previously reported validated/
putative cancer drivers could also account for metabolic
dysregulation of the 44 core metabolic drivers or could
be linked with the selection of SCNAs. To answer this,
we compiled a comprehensive list of previously reported
cancer drivers from three established sources [17–19]
and tested whether our core metabolism signature was
associated with the somatic mutational events under-
lying these drivers. Significant overlap (71 genes, P <
10−4; permutation analysis) was observed amongst the
three sources of cancer drivers and a smaller but still
significant overlap of four genes (B4GALT3, CYC1,
GMPS and SLC25A10) was observed between the
combined list from the three databases and the meta-
bolic signature (P = 0.045, hypergeometric test)
(Fig. 2a).
We further tested the likelihood of observing these
previously reported cancer drivers (somatic mutations
driven) in any of the 2752 metabolism genes and ob-
served that metabolism genes were significantly enriched
in the non-mutated component of the genome (the over-
lap with CGC drivers was 26 genes, P < 1 × 10−5; with
Kandoth drivers it was seven genes, P = 1.4 × 10−4; with
Tamborero drivers it was six genes, P = 4 × 10−5; 105
permutations; see the “Permutation analysis” section in
the “Methods”). Since the cancer drivers in these three
databases [17–19] were catalogued mainly based on
somatic point mutations and indels (with the exception
of CGC, which also contained amplifications, transloca-
tions and germline mutations), we assessed whether core
metabolic signature genes exhibit SCNAs preferentially.
By comparing the proportions of samples that had only
SCNAs or only mutations, we conclude that core meta-
bolic signature genes indeed have a tendency to harbour
SCNAs as opposed to somatic mutations (Additional file 1:
Figure S5d). This finding agrees with the previously
illustrated cancer genome hyperbola model which depicts,
on a whole genomic scale, SCNAs to be inversely corre-
lated with mutational events [34].
Owing to this limited overlap between the metabolic
signature and previously reported cancer drivers, we
asked whether any association exists between the mRNA
profiles of these cancer drivers and the metabolic signa-
ture (“Methods”). First, the background distribution of
mRNA–mRNA correlation between random gene pairs
was established for each cancer type (one million per-
mutations; see the “Permutation analysis” section in the
“Methods”; Fig. 2b; Additional file 1; Additional file 2:
Table S10). Next, correlation analysis was performed
between mRNA profiles of the core metabolic signature
and mRNA profiles of (1) cancer-type specific candidate
drivers [18] mutated in at least 5 % of the cohort and (2)
a merged global high-confidence cancer gene consensus
list [18, 19] (Additional file 1 and Additional file 2:
Table S11). Cancer-type specific analysis revealed modest
to strong correlation between the expression of previously
reported cancer drivers and at least some of the 44 core
metabolic drivers, except for OV, where no significant
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correlation was identified (Fig. 2c). Conversely, the ana-
lysis of the global list of 180 previously reported cancer
drivers showed a correlation between a large proportion
of these 44 genes and at least the expression of one cancer
driver gene (Fig. 2d) and revealed a subgroup of these
genes (Fig. 2d, orange covariate) significantly associated
with expression of several previously reported cancer
drivers across cancers (P < 0.05; 10,000 random permuta-
tions; see the “Permutation analysis” section in the
“Methods”). These genes were enriched in drug, pyrimi-
dine and purine metabolism (q values 8.34 × 10−8 to
0.0001, minimum overlap of three genes). In contrast, a
A
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Fig. 2 Metabolic compartmental enrichment and candidate drivers of tumourigenesis. a Overlap of genes between the core candidate metabolic
drivers (yellow) and three lists (blue, purple and green) of previously reported cancer drivers [17–19]. The number in white (71) indicates overlap
between the previously reported cancer drivers. b Pan-cancer null distributions of Spearman’s correlation coefficients between mRNA profiles of
one million random (matched across tumour types) gene pairs. c, d Pan-cancer enrichment analysis of previously reported cancer-specific drivers
(c) and the global (combined) list of candidate cancer drivers (d). The numbers in the cells indicate the total number of drivers correlated or anti-
correlated with the corresponding metabolic gene (rows). The cutoffs for correlation were derived from the null distribution (95th and 5th percentiles)
as shown in Fig. 2b. The cell colour indicates the probability values of expecting the observed correlation by random chance alone, with high intensities
suggesting higher enrichment of previously reported cancer drivers in genes correlated with the candidate metabolic drivers. Tumour types (columns)
were grouped by hierarchical clustering. The gene-wise (rows) clustering groups for the merged list of cancer drivers (d) are highlighted in orange (high
correlation group) and blue (low correlation group). e, f Density plots of Spearman’s correlation coefficients of candidate metabolic drivers exhibiting
significant correlation with the cancer-specific (e) and global list of previously reported cancer drivers (f). BLCA bladder urothelial carcinoma, BRCA breast
invasive carcinoma, COADREAD colorectal adenocarcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KIRC kidney
renal clear cell carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV Ovarian serous cystadenocarcinoma, UCEC uterine
corpus endometrial carcinoma
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second subgroup showed a weak correlation with expres-
sion of previously reported cancer drivers (Fig. 2d, blue
covariate) and no enrichment in any biological pathway.
In both analyses, inspection of the correlation values re-
vealed a strong overall trend of inverse correlation be-
tween the expression of the 44 core metabolic signature
genes and that of previously reported cancer drivers
(Fig. 2e, f ).
Finally, we compared the mRNA profiles of metabolic
genes by stratifying them into mutant and wild-type
groups using each of the cancer type-specific drivers.
Significant differences (|log2 fold change| > 1, q value <
0.1) in mRNA abundance for eight metabolic genes
(with sparse overlap between five cancer types) were ob-
served, demonstrating limited dependence on the muta-
tional status of previously reported cancer drivers (TP53,
ATRX, IDH1, NFE2L2, BAP1, USP9X and KEAP1)
(Additional file 1 and Additional file 2: Table S12).
In summary, these results indicate that SCNAs are the
main events underlying over-expression of the 44 core
candidate metabolic drivers, although they also suggest
that previously reported (non-metabolic) cancer drivers
may contribute to a dysregulated metabolism via indirect
regulation of metabolic genes.
Clinical relevance of the newly identified candidate
metabolic drivers
We asked whether the mRNA abundance profile of the
44 candidate metabolic drivers is a prognostic indicator,
further substantiating gain of function. Univariate sur-
vival analysis of cancer type-specific candidate metabolic
drivers revealed a number of genes that were prognostic
(11 BRCA, two COADREAD, one GBM, three KIRC,
two lung squamous cell carcinoma (LUSC) and six OV;
P < 0.05, log-rank test; Additional file 1 and Additional
file 2: Table S13). By pre-selecting prognostic genes
(P < 0.1, log-rank test) over 1000 cross-validation itera-
tions, we trained multivariate prognostic models includ-
ing clinical variables for breast cancer and tested them
on held-out subsets of the respective cohorts (see the
“Survival analysis” section in the “Methods”). The BRCA
(median concordance index = 0.63) and KIRC (median
concordance index = 0.62) classifiers were consistently
prognostic (1000 classifiers on randomly generated
training sets) (Fig. 3a).
Importantly, BRCA prognostic classifiers were vali-
dated on an independent Metabric breast cancer cohort
[15] (median concordance index = 0.61), indicating the
robustness of the breast cancer classifiers. The BRCA
classifiers were most frequently composed of clinical
stage and three core metabolic signature genes (SQLE,
ALG3 and PSPH) whilst KIRC classifiers predominantly
constituted two core metabolism genes (NUDT1 and
GAPDH) (Fig. 3b). COADREAD, GBM, LUSC and OV
prognostic classifiers did not validate on their respective
validation sets (Fig. 3a). Using the most frequently se-
lected metabolism genes in breast cancer, a multivariate
molecular classifier was created using the entire TCGA
BRCA cohort and was successfully validated in the
Metabric cohort (hazard ratio (HR)Q4 vs Q1 = 2.49, P =
1.11 × 10−16; Additional file 1: Figure S6a). Since clinical
stage demonstrated a strong tendency of selection in the
permutation analysis, we adjusted the molecular classi-
fier for clinical stage and it remained an independent
predictor of patient outcome (HRQ4 vs Q1 = 1.89, P =
6.45 × 10−7; Additional file 1: Figure S6b).
Subtype-specificity and hypoxia association of metabolic
drivers
Cancer types and subtypes are heterogeneous [21, 24, 28].
We focused on breast cancer, where the presence of many
different subtypes has been extensively reported [15], and
A B
Fig. 3 Prognostic significance of candidate metabolic drivers. a Distribution of concordance indices in held-out validation set/s using 1000 prognostic
classifiers for each cancer type (see the “Survival analysis” section in the “Methods” ). The dashed grey line (concordance index = 0.5) represents a model
with no prognostic ability. For breast cancer, models were trained using half of the TCGA cohort and tested on the other half as well as independently
tested on the Metabric cohort. b Percentage inclusion of the most frequently chosen genes in each cancer type (>20 % of models) following univariate
and LASSO feature selection performed on the training cohort. Red asterisks indicate genes present in the core metabolic signature
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also observed the strong association between hypoxia, gen-
omic alterations and metabolism (Fig. 1; Additional file 1:
Figure S1). We asked if genomic and clinical heterogeneity
in breast cancer could be associated with metabolic
differences. We used an independent cohort (Metabric)
[15] further stratifying by well-known breast cancer sub-
types (PAM50) [35]. Of the 103 (97 mapped to Metabric)
candidate metabolic genes identified in the TCGA BRCA
series (Additional file 1 and Additional file 2: Table S4), 49
maintained a positive correlation between mRNA abun-
dance and copy number gains in the Metabric cohort
(compared with 63 in the BRCA cohort) (ρ > 0.3, q < 10−3;
Additional file 1 and Additional file 2: Table S14). The
subtype-specific analysis revealed 19 core breast cancer
metabolic genes present in all subtypes, as well as genes
exclusive to aggressive subtypes (Basal-like, Her2-
enriched and Luminal B; Fig. 4a; Additional file 1 and
Additional file 2: Table S14). The number of genes
showing positive mRNA–DNA correlations within each
subtype was variable, with the highest in the aggressive
subtypes: basal-like (50/97, P = 2 × 10−4) and Her2-
enriched (52/97, P < 10−4) diseases (Additional file 1 and
Additional file 2: Table S15).
The subtype-specific candidates showed some, although
limited, overlap of five genes with previously reported
cancer drivers (Additional file 1: Figure S7a–e). Next, we
inspected the genomic distribution of breast cancer
candidate metabolic drivers and previously reported
cancer drivers. Examination of co-occurrence of genes in
proximal chromosome bands revealed five clusters (which
included nine metabolic genes) whereby genomic gains
were significantly collocated. For instance, gain in
chromosome 8q24 of MYC was significantly associated
with SQLE, PYCRL, TSTA3, CYC1 and SLC39A4 (P = 0 to
3 × 10−283, Fishers exact test; Fig. 4b; Additional file 1 and
Additional file 2: Table S16).
A similar trend was maintained in basal-like, Her2-
enriched and luminal B breast cancers (PBasal = 6.56 × 10
−53
to 1.96 × 10−38, PHer2 = 5.48 × 10
−54 to 4.37 × 10−27, PLumB =
1.34 × 10−106 to 1.81 × 10−78; Fishers exact test; Fig. 4b;
Additional file 1 and Additional file 2: Table S16), in line
with previous studies demonstrating a link between MYC
co-amplification and these genes as well as association with
poor prognosis [36, 37]. Analysis of mRNA and DNA
profiles on the chromosome 8q24 locus emphasised the
importance of these five metabolism genes as they all
demonstrated greater than average concordance between
mRNA and DNA profiles (Fig. 4c).
As hypoxia is a driver of genomic gains (Additional file 1:
Figure S1b, c) [32], we tested hypoxic association of SCNAs
in these five genes, confirming significant positive correl-
ation between SCNAs and the hypoxia signature [20]
(Spearman’s ρ: SQLE = 0.31, PYCRL = 0.25, TSTA3 = 0.25,
CYC1 = 0.25, SLC39A4 = 0.24; P < 10−3).
Of the five MYC co-amplified candidate metabolic
drivers, CYC1 and TSTA3 demonstrated significant asso-
ciation with poor survival using both DNA- and mRNA-
based groupings (CYC1SCNA: HR = 1.26, 95 % confidence
interval (CI) = 1.08–1.47, P = 0.003; CYC1mRNA: Pquartiles
= 3.9 × 10−5; TSTA3SCNA: HR = 1.28, 95 % CI = 1.1–1.49,
P = 0.002; TSTA3mRNA: Pquartiles = 0.037) but SQLE dem-
onstrated the highest prognostic ability on both
mRNA- and DNA-derived risk groups (Fig. 4d–g).
Since we observed a modest increase in SQLE mRNA
abundance in the TP53 mutant group in breast cancer
(Additional file 1 and Additional file 2: Table S12),
we further interrogated this association with TP53
mutation status in the TCGA breast cancer cohort
(where all data modalities were available) and found
that SQLE’s prognostic ability was decreased when
adjusting for TP53 mutation status (P = 0.03 to 0.18)
(Additional file 1: Figure S8). However, SQLE’s mRNA
association with prognosis was independent of MYC
gain/amplification as we could recapitulate it in MYC
neutral cases. Furthermore, following adjustment for
clinical covariates (age, stage and grade), SQLE genomic
classification remained an independent prognostic factor
(HR = 3.2, 95 % CI = 1.64–6.26, P = 6.64 × 10−4) (Additional
file 1 and Additional file 2: Table S17). Importantly, stratifi-
cation of SQLE’s median-dichotomised (mRNA) risk groups
by the hypoxia signature [20] indicated a worse prognosis
group associated with SQLE over-expression in hypoxic tu-
mours (Fig. 4h).
Next, we extended our breast cancer candidate meta-
bolic drivers by repeating the analyses on each of the
PAM50 subtypes in a large breast cancer series having
sufficient representation of all subtypes (Additional file 1
and Additional file 2: Table S18). These data indicated 12
core genes common across all subtypes, including SQLE
and SLC39A4 (Additional file 1: Figure S7F) as core meta-
bolic drivers of all breast cancers. We also tested these
subtype-specific candidate metabolic genes for the pres-
ence of subtype-specific mutational events using the
TCGA BRCA study [25]. Consistent with our previ-
ous observation of lack of mutational events in candi-
date metabolic drivers, none of the subtype-specific
metabolic genes were significantly mutated.
In summary, our results indicate that the heterogen-
eity in breast cancer subtypes can be partially recapit-
ulated by underlying metabolic signatures. These
subtype-specific breast cancer metabolism signatures
contained a common set of five genes (SQLE, PYCRL,
TSTA3, CYC1 and SLC39A4) which were co-amplified
with MYC on chromosome 8q24 and showed a posi-
tive correlation with hypoxia. Of these genes, SQLE
SCNA as well as mRNA profiles were associated with
poor clinical outcome in an independent breast can-
cer cohort, with worse prognosis in hypoxic tumours.
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The top ranked, MYC co-amplified, metabolic driver SQLE
is key for cell survival under hypoxic conditions
Focussing on the MYC locus (chromosome 8q24), we
sought to elucidate the role of five candidate metabolism
drivers (SQLE, PYCRL, TSTA3, CYC1 and SLC39A4). All
of these genes have shown varying but significant levels
of essentiality in previous cell line shRNA screens [38]
(Additional file 1 and Additional file 2: Table S19). Of
these, SQLE was not only ranked amongst the top candi-
dates in our analysis but also displayed putative gains/
amplifications in breast cancer cell lines from the Cancer
Cell Line Encyclopaedia (CCLE) [39] (Additional file 1:
A
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Fig. 4 Independent validation of candidate metabolic drivers in the Metabric breast cancer cohort (n = 1991). a The overlap of candidate metabolic
drivers identified in the TCGA BRCA cohort and tested for the correlation between mRNA and gene copy number data (log2 ratio) in the Metabric
cohort. The numbers indicate correlated genes in the intrinsic subtypes of breast cancer (PAM50). Due to absence of subtype-specific candidate
metabolic genes in the PAM50 subtype ‘Normal-like’ breast cancer, it was not considered in subsequent analyses. b Genome-wide altered copy number
fraction in the complete Metabric cohort (n = 1991). Bottom: pink peaks indicate fractional copy number gains/amplifications; blue peaks indicate
fractional homozygous or heterozygous deletions. The gene symbols of candidate metabolic genes are located at the top in the order of their genomic
location (left to right: chromosome 1 to X). Gene symbols with asterisks indicate significantly altered known breast cancer genes [25], MYC and ERBB2.
Genes in red represent clusters of metabolic and significantly altered breast cancer genes that are in genomic proximity of each other. The red dashed
lines show their approximate loci. Top: heat map showing the presence (blue) and absence (grey) of candidate metabolic genes across breast cancer
intrinsic subtypes (PAM50) (as summarised in Fig. 4a). The subtype-specific significantly altered known breast cancer genes [25] are also highlighted
with asterisks. c Correlation between mRNA and copy number data for genes in chromosome 8q24 amplicon using the complete Metabric cohort
(All) and intrinsic subtypes of breast cancer. The candidate metabolic drivers are highlighted with unique symbols to show their mRNA dependence on
gene dosage. d Copy number-based Kaplan–Meier analysis of SQLE in the Metabric breast cancer cohort. There were only five cases for which copy
number state = heterozygous loss and, therefore, these were merged with the copy number diploid (NEUT, n = 1282) group. Genomic gains and
amplifications were collapsed into one group (GAIN). e Same as (d) using the MYC diploid/loss subset of the Metabric breast cancer cohort. f mRNA-
based Kaplan–Meier analysis of SQLE in the Metabric breast cancer cohort. Samples were split into four groups based on 75th percentile, median and
25th percentile of log2 mRNA abundance of SQLE (lowest =Q1, highest =Q4). g mRNA-based Kaplan–Meier analysis of SQLE in the MYC diploid/loss
subset of the Metabric breast cancer cohort. h Median-dichotomised mRNA-based Kaplan–Meier analysis of SQLE further stratified into hypoxia high
and low risk groups (S0H0= low SQLE and low hypoxia, S0H1= low SQLE and high hypoxia, S1H0= high SQLE and low hypoxia, S1H1= high SQLE and
high hypoxia). BC breast cancer, OS overall survival
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Figure S9a–d). We further verified SQLE copy number
gains and mRNA correlation in both breast and colorec-
tal cancer cell lines (Fig. 5a, b). In general, our findings
from the clinical studies were corroborated in the CCLE
by the correlation patterns between the DNA and
mRNA profiles of candidate metabolism drivers
(Additional file 1: Figure S10a–d). Given the positive
correlation of five candidate metabolic genes located at
MYC amplicon genes with the hypoxia gene expression
signature in breast cancer (Spearman’s ρ: SQLE = 0.31,
PYCRL = 0.25, TSTA3 = 0.25, CYC1 = 0.25, SLC39A4 =
0.24; P < 10−3), we tested whether these five genes are
directly induced by hypoxia and/or, when expressed,
confer survival advantage under hypoxia. In vitro mRNA
abundance analysis under hypoxia and normoxia re-
vealed strong hypoxic dependence for SQLE in
HCC1569 and HCC1806 breast cancer cells and
HCT116 colorectal cancer cells (P < 0.05; unpaired t-
test) (Fig. 5c, d). Analysis of SQLE protein expression
confirmed hypoxic induction of SQLE in HCC1806 and,
to a lesser extent, in HCC1569. None of the other
chromosome 8q24 genes demonstrated hypoxic regula-
tion (Additional file 1: Figure S11a–d). We validated the
copy-number of SQLE and MYC in the breast and
colorectal cell lines relative to the genome ploidy with
quantitative PCR (Additional file 1: Figure S12). With
the exception of HCC1954 and MDA-MB-231, all other
cell lines had a significantly increased number of copies
of SQLE (P < 0.05, unpaired t-test). TheMYC copy number
was also significantly increased (P < 0.05, unpaired t-test)
in all cell lines except HCC1569 cells.
SQLE requires oxygen as a co-factor for its enzymatic
reaction; thus, we hypothesised that it may show
decreased activity in hypoxia and the selection of early
genes in the cholesterol biosynthesis pathway for ampli-
fication in hypoxia, such as HMG-CoA reductase [40],
may contribute to overcome the block. The increased
amount of SQLE may compensate for decreased activity
in hypoxia. The relative expression of SQLE at the
mRNA (Fig. 5e) or protein (Fig. 5f ) levels did not show
any significant relationship to DNA copy number. This
suggests other mechanisms such as epigenetic regulation,
as shown previously [37], may also play a role in increas-
ing SQLE expression in tumours.
Given SQLE’s MYC-independent prognostic ability
(Fig. 4e, g), association with hypoxia in breast and colo-
rectal cancer samples (Spearman’s ρ: Breast-Metabric =
0.31, Breast-BRCA = 0.42, P < 10−3; COADREAD = 0.17,
P = 0.003) and hypoxic induction in three cell lines
amongst those tested (Fig. 5c), we focussed on functional
analysis of SQLE. Breast and colorectal cancer cells were
treated with SQLE inhibitor (NB-598) under hypoxia
and normoxia (Fig. 5g–j). There was no effect on cell
viability in GI50 assays under normoxic conditions, but
the highly amplified triple negative breast cancer cell line
HCC1806 and modestly amplified colorectal cancer cell
line DLD-1 showed clear sensitivity to NB-598 under
hypoxia (1 % O2; Fig. 5g, j). We further investigated the
functional significance of SQLE by clonogenic assay
(Fig. 6a–g). One cell line showed reduced survival in
hypoxia alone (P < 0.001); however, in six of the seven
cell lines tested, there was a significant synergistic effect
of SQLE inhibition and hypoxia. Equivalent knockdown
analyses on TSTA3 and PYCRL, two of the other four
top candidate metabolism genes, followed by cell viability
and clonogenic assays indicated a smaller yet significant
effect for PYCRL knockdown; in particular, PYCRL knock-
down reduced the number of colonies in HCC1806 and
DLD-1 cells only under hypoxia (P < 0.05; Additional
file 1: Figure S11e–p).
In summary, SQLE expression in vitro demonstrated
significant increases under hypoxia in three of the seven
breast and colorectal cancer cell lines. SQLE was also
confirmed as a driver of colorectal and triple receptor
negative breast cancers and a key gene in maintaining
cell survival under hypoxia.
Discussion
The metabolism of rapidly dividing tumour cells is
shifted towards increased anabolic processes and redox
homeostasis compared with normal cells. Further, the
hypoxic microenvironment adds additional metabolic
stress, to which tumour cells have to adapt. Indeed,
much research over the past decade has shown increased
expression of and dependence on many genes involved
in the tumour hypoxic microenvironment [41]. More-
over, complex interactions between oncogenic signalling
pathways such as MYC and metabolism have been
identified [2, 4, 6, 42]. Essential metabolic pathways hold
potential to offer new druggable targets [43] and have
served as therapeutic targets in a number of cancer
types. In order to systematically identify new potential
targets, we devised and exploited a novel in silico ap-
proach revealing metabolic dysregulation as an under-
lying source of selective genomic heterogeneity in a
large pan-cancer study.
In a comprehensive analysis of 6538 samples from ten
different cancer types, considering both genotypic
(DNA) and phenotypic (mRNA and clinical prognosis)
data , we show that over-expression of metabolic genes
is substantially enriched with somatically acquired gains
and amplifications. Our results suggest that these
genomic alterations form a core part of the metabolic
reprogramming that is conserved across different cancer
types. Specifically, we identified a core signature of 44
metabolic drivers and revealed tumour site-specific meta-
bolic genomic landscapes. We present evidence that dif-
ferential metabolic requirements contribute to genomic
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heterogeneity amongst tumours and aggressiveness
specifically in kidney and breast cancers. Core metabolic
prognostic signatures are identified, comprising NUDT1
and GAPDH in kidney renal cell carcinoma and SQLE,
ALG3 and PSPH in two independent breast carcinoma
cohorts. Importantly, this identifies patients who might
benefit from treatment with inhibitors of these genes,
which in some cases are already being tested pre-clinically
(e.g. GAPDH [44] and NUDT1 [45] inhibitors).
Importantly, we show that both copy number amplifi-
cation and expression of the identified metabolic driver
genes are significantly associated with tumour hypoxia,
suggesting a mechanism of metabolic reprogramming
via adaptation within a hypoxic tumour microenviron-
ment. We complement this analysis with evidence from
in vitro and in vivo models supporting the hypothesis of
selection pressure under hypoxia.
Amongst the top ranked candidates, we show SQLE is
a metabolic driver in multiple cancers and demonstrate
its association with prognosis and tumour hypoxia
(Figs. 1 and 3). Importantly, high SQLE expression in
hypoxic tumours was significantly associated with poor
survival. SQLE is often co-amplified with the cancer driver
MYC but SQLE expression is prognostic independent of
MYC status. Furthermore, functional characterisation
demonstrates SQLE’s specific role in maintaining prolifer-
ative integrity and regulating cell survival exclusively
under hypoxia in a panel of cancer cell lines and inde-
pendently of MYC amplification, confirming SQLE as a
potential driver of selection under hypoxia. Interestingly,
SQLE protein has also been detected in exosomes of
breast cancer cells (MDA-MB-231) [46]. A recent study
has also demonstrated that over-expression of SQLE
promotes cell proliferation and migration and acts as a
positive regulator of ERK signalling in hepatocellular
carcinoma cells [47]. A second study, published while this
manuscript was in revision, independently confirmed
SQLE as bona fide oncogene by amplification, further
supporting our findings [48]. SQLE catalyses a rate-
limiting oxygenation step in sterol biosynthesis. Choles-
terol is vital to cell membrane structure and also functions
as a precursor of fat-soluble vitamins and steroid hor-
mones [49]. It also forms part of lipid rafts which co-
ordinate receptor-mediated signal transduction pathways
[50]. Of the pan-cancer metabolic signature, SQLE and
DHCR7, which catalyses cholesterol synthesis, were re-
cently identified as the mediators of radiotherapy resist-
ance in pancreatic cancer [51]. Hypoxic accumulation of
squalene, the substrate of SQLE, occurs in glioblastoma,
likely due to the dependence on oxygen as a co-factor for
SQLE catalysis [52].
In summary, our study highlights a key role for
hypoxia as a driver of genomic adaptation, including
metabolic genes not directly induced by hypoxia and not
previously identified as cancer drivers, such as SQLE.
Importantly, drug inhibitors exist for several of the
identified genes, allowing prompt translation and testing
of these findings in clinical trials, with appropriate
patient selection.
Conclusions
Our pan-cancer analysis of genomic and transcriptomic
profiles reveals a conserved landscape of metabolic
dysregulation in human cancers linked with tumour
hypoxia. We identified a core group of candidate meta-
bolic driver genes as amplified and over-expressed across
cancer types and strongly associated with tumour hyp-
oxia in terms of both expression and DNA copy number.
We also show that these metabolic drivers had not been
previously identified as tumour suppressor and/or onco-
genes and their over-expression in cancer cannot be ex-
plained by genomic alterations in known cancer drivers.
Amongst the top candidate metabolic drivers for which
drug inhibitors exist, we show that SQLE is independ-
ently prognostic and plays a key role in maintaining cell
survival under hypoxia.
Methods
Pre-processing and filtering
mRNA abundance, DNA copy number and somatic
mutation profiles for TCGA datasets were downloaded
from TCGA DCC (gdac), release 2014-01-15. For mRNA
abundance, Illumina HiSeq rnaseqv2 level 3 RSEM
normalised profiles were used. Genes whereby >75 % of
samples had zero reads were removed from the respective
dataset. GISTIC v2 [53] level 4 data were used for copy
(See figure on previous page.)
Fig. 5 In vitro validation of SQLE is normoxia and hypoxia. a SQLE expression and copy number correlation in CCLE breast cancer lines. Cell lines
used for in vitro validation are labelled. b SQLE expression and copy number correlation in CCLE colorectal cancer lines. Cell lines used for in vitro
validation are labelled. c SQLE expression in cancer cell lines under 24-h normoxia and hypoxia (1 % O2). d CA9 expression (hypoxia control) in
cancer cell lines under 24-h normoxia and hypoxia (1 % O2). e SQLE expression in cancer cell lines relative to one another. f Western blot analysis
showing the levels of SQLE, MYC, phospho-MYC (Ser62), HIF-1α and CA9 after 24 h of normoxia and hypoxia (1 % O2). The two SQLE bands correspond
to different isoforms, which were further confirmed by siRNA knockdown western blots (Additional file 1: Figure S11q). g–j SQLE inhibition with NB-598
reduces cell viability at a range of concentrations with a GI50 of 6 nM in HCC1806 (g) and GI of 10.9 nM in DLD-1 (j) under hypoxia (1 % O2) but not
normoxia. The effect of the compound was not inhibitory enough to calculate a GI50 value in MDA-MB-231 (h) or HCT116 (i) cells under normoxia or
hypoxia (1 % O2). HCC1954 and HCC1569 are HER2+ breast cancer cell lines. MDA-MB-453, HCC1806 and MDA-MB-231 are triple receptor negative
breast cancer cell lines. HCT116 and DLD-1 are colorectal cancer cell lines. Error bars are standard deviations. ***P < 0.001, **P < 0.01, *P < 0.05, n = 3
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number analysis and log2 ratios were processed to call
SCNA states (human genome assembly Hg19). Briefly,
SCNA gains/amplifications were based on 0: t < 0.2; 1:
0.2 ≤ t ≤ 1; 2: t > 1 and losses were based on 0: t > −0.2; −1:
−0.2 ≥ t ≥ −1; −2: t < −1, where t denotes the log2 ratio.
Level 1 clinical data were used for survival analysis. TCGA
GBM and OV cancer microarray data were used for
mRNA differential expression analysis as normal samples
were not available on the Illumina HiSeq platform. mRNA
data were converted to log2 scale for subsequent analyses.
Analysis of differential mRNA abundance of candidate
metabolic drivers stratified by mutational status of cancer
type-specific drivers was based on TCGA DCC-reported
MutSig v2.0 calls.
The Metabric breast cancer dataset was pre-processed,
summarised and quantile-normalised from the raw
expression files generated by Illumina BeadStudio (R
packages: beadarray v2.4.2 and illuminaHuman
v3.db_1.12.2). Raw Metabric files were downloaded
from the European Genome-phenome Archive (EGA;
study ID EGAS00000000083). Data files of one
Metabric sample were not available at the time of our
analysis and were therefore excluded. Probe to gene-level
mapping was performed by keeping the most variable
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Fig. 6 Clonogenic analysis of SQLE. a–g Clonogenic analysis of SQLE inhibition by NB-598 under normoxia and hypoxia (1 % O2) in HCC1954
(a), HCC1569 (b), MDA-MB-453 (c), MDA-MB-231 (d), HCC1806 (e), DLD-1 (f) and HCT116 (g) cells. ***P < 0.001, *P < 0.05, n = 3. Black, red, blue and
green bars correspond to the percentage of colonies under normoxia and hypoxia and NB-598 cells under normoxia and hypoxia, respectively.
Error bars are standard deviations
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(standard deviation) probe. Log2 scaled data were used for
differential expression analysis. Metabric copy number
segmented genomic region data as published in the
original study [15] (human genome assembly Hg18) were
processed to create gene by patient log2 ratio and call
profiles.
Processing of xenograft samples
Mice were housed at BMS, University of Oxford, UK
and procedures were carried out under a Home Office
license. Six- to seven-week-old female BALB/c NuNu
mice were injected subcutaneously in the lower flank
with 100 μl Matrigel (BD Bioscience) and 1 × 107
HCT116 cells suspended in 100 μl of serum-free
medium. Tumour growth was monitored three times
per week measuring the length (L), width (W) and
height (H) of each tumour using calipers. Volumes were
calculated from the formula 1/6 × π × L ×W×H. For
bevacizumab treatment mice were injected intraperito-
neally every 3 days (10 mg/kg) until sacrifice once
randomised groups had xenografts which had reached
an average of 150 mm3 in size. When tumours reached
1.44 cm3 the mice were sacrificed by cervical dislocation.
Pre-processing of Affymetrix CytoScan HD data
Affymetrix CytoScan HD array profiling was performed
on three untreated HCT116-derived xenografts and
three bevacizumab-treated samples. Data were normal-
ised to a large collection of reference human normals as
packaged with R package rawcopy (v1.0). Resulting logR
ratio data were segmented using rawcopy’s default
segmentation algorithm, PSCBS (Additional file 1 and
Additional file 2: Table S20). Gene mapping to seg-
mented regions was performed by rawcopy using RefSeq
annotation. Since xenografts were exposed to bevacizu-
mab for a limited period of time, we used relatively
lenient logR ratio thresholds of ±0.1 for copy number
gains and losses (Additional file 1 and Additional file 2:
Table S21). Genes which were split in regions of gain as
well as loss in the bevacizumab-treated groups were
filtered out from subsequent analysis. Raw Affymetrix
CEL files are available through the EBI Array Express
portal (http://www.ebi.ac.uk/arrayexpress/) under acces-
sion number E-MTAB-4200.
Fraction of transcriptome altered (genomic instability
marker)
Genome instability in different gene sets (core metabol-
ism signature, non-core metabolism, all metabolism and
rest of the genome) was estimated at the gene level. For
each gene, the fraction of patients with copy number
calls 1,2 (gain/amplified) were regarded as the gained
fraction and copy number calls −1,−2 were classed as
the loss fraction. Across all gene sets, the fractions
altered per gene were averaged to estimate an overall
measure of the fraction of the cohort altered. This was
estimated separately for gains and losses.
Differential gene expression analysis
Differentially expressed genes were identified using Welch’s
t-test. P values were adjusted for multiple comparisons
using the Benjamini–Hochberg method. Genes with log2
fold change >0.5 and q < 0.05 (Benjamini–Hochberg
method) were regarded as over-expressed, except for
bladder urothelial carcinoma (BLCA), ovarian serous cysta-
denocarcinoma (OV) and uterine corpus endometrial car-
cinoma (UCEC), for which only a log2 fold-change >0.5
threshold was applied to keep the initial feature selection
sets (top 10 % over-expressed metabolic genes) a similar
size.
Correlation analysis
All correlation analyses (mRNA–mRNA and mRNA–log2
copy number ratio) were performed using Spearman’s
rank correlation.
Pathway analysis
Pathway enrichment analysis for human samples was
conducted using GeneCodis [54] against the KEGG
database.
Permutation analysis
The null distribution to estimate the enrichment of
highly correlated metabolic genes at the mRNA and
DNA levels was estimated by randomly selecting 10,000
genes from the non-metabolic section of the transcrip-
tome. The gene set size was matched to the cancer type-
specific size of genes exhibiting over-expression and
gains/amplification (>20 %) in the metabolic genome.
Null distributions for mRNA–mRNA correlation for
each cancer type were established by randomly sampling
two distinct sets of 1000 genes, resulting in one million
random correlations matched across cancer types. The
reference distribution for mRNA–SCNA log2 profiles
was established on common genes across all ten cancer
types (14,923 genes).
Cancer-specific lists of candidate drivers were ex-
tracted from Kandoth et al. [18], further limiting the list
to genes which showed >5 % mutation frequency in the
respective cohorts. A global list of previously reported
cancer drivers was compiled as a merged list of all
Kandoth et al. genes and Tamborero et al. [19] putative
drivers annotated as ‘High Confidence Driver’ and also
present in the Cancer Gene Consensus [17]. For each
cancer type, mRNA–mRNA correlations were estimated
between core candidate metabolic drivers and the
above-mentioned known candidate driver lists. Using
the 95th and 5th percentile thresholds of null
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distributions for mRNA–mRNA correlations, correlation
counts tables (Fig. 2c, d) were established. The probabil-
ity values for each cell (Fig. 2c, d) were estimated by ran-
domly sampling 10,000 subsets of genes and counting
the number of times core candidate metabolic drivers
showed correlation counts greater than observed. The
same procedure was repeated for both cancer-specific
candidate drivers (Fig. 2c) and the global list of candi-
date drivers (Fig. 2d).
Null distributions for overlap between metabolism
genes and CGC, Kandoth et al. and Tamborero et al.
drivers (as described previously) were estimated by
generating 100,000 random subsets of genes from the
non-metabolism part of the genome. Probabilities of
observing an overlap with metabolism genes as low as
26 (CGC), 7 (Kandoth) and 6 (Tamborero) were subse-
quently estimated using the randomly generated counts.
Co-occurrence analysis
We established a 2 × 2 counts table for each pair of
genes using copy number call data. For each pairwise
comparison, the table contained counts for when both
genes had amplification, counts exclusive to one gene
and counts for when neither had amplification. Due to dif-
ferent copy number-calling algorithms, for the Metabric
dataset, gains and amplifications were treated as one
category (amplifications). Fisher’s exact test was used to
estimate the co-occurrence of copy number amplifications
between a given pair of genes.
Gene essentiality estimation
Gene essentiality estimates were generated in a panel of
breast cancer cell lines using the COLT cancer database
[38] (http://dpsc.ccbr.utoronto.ca/cancer). Data were
filtered using default parameters, limited to breast
cancer cell lines and a GARP (Gene Activity Ranking
Profile) score P value <0.1.
Cancer cell line encyclopaedia analysis
mRNA abundance and gene copy number log2 ratio data
from the CCLE were downloaded from the Broad Institute
(http://www.broadinstitute.org/ccle/). For gene copy num-
ber status, a threshold of 0.2 and –0.2 (consistent with
thresholds used for patient data) was applied to log2 ratio
profiles to determine putative gains/amplifications and
losses, respectively. Breast cancer cell line subtype classifi-
cations were inferred from previously published data [55].
Survival analysis
Survival modelling was limited to cancers with available
survival data: BRCA, COADREAD, GBM, KIRC, LUSC,
OV and Metabric. A Cox proportional hazards model
was used to estimate the hazard ratio and a Wald test
was used to test the significance of outcome difference
between the risk groups. For univariate analysis, mRNA
abundance profiles were median-dichotomised to
established high-risk (high-abundance) and low-risk
(low-abundance) groups. Overall survival time was trun-
cated at 10 years for all cancers except for aggressive tu-
mours (GBM, Metabric’s basal-like and Her2-enriched
subtypes), where the truncation was done at 5 years.
For multivariate analysis, genes with correlated mRNA
and copy-number profiles were selected by cancer type
(BRCA, COADREAD, GBM, KIRC, LUSC and OV;
Additional file 1 and Additional file 2: Table S5).
Cohorts were randomly split into two halves (training
and validation cohorts), except GBM, which was split
2:1 due to the small number of samples (n = 154). For
each cancer type, genes were pre-selected through a
univariate Cox proportional hazards model followed by
log-rank test (P < 0.1; training cohort only). Selected
genes were taken forward for multivariate Cox modelling
with LASSO feature selection (L1 penalty) in a tenfold
cross-validation setting. The model with the smallest
mean cross-validation error was selected and tested on
the held-out validation cohort. For BRCA, all models
contained clinical covariates of age (dichotomised at
50 years) and stage (1 = baseline, 2, 3, 4). These were
also tested on the fully independent Metabric breast
cancer cohort. Predicted response scores and predicted
risk were evaluated for survival association in validation
set/s using the concordance index.
Survival modelling was performed in the R statistical
environment (v3.0.1) using the R packages survival
v2.37-4, glmnet v1.9-5, glmpath v0.95, survcomp v1.10.0
and randomForestSRC v1.4.
Cell culture, GI50 and clonogenic analysis
Cells were maintained in a humidified incubator at 5 %
CO2 and 37 °C. For hypoxic exposure, cells were grown
at 1 % O2, 5 % CO2 and 37 °C in an INVIVO2 400
(Baker Ruskinn, USA).
MDA-MB-231, MDA-MB-453 and HCT116 cells were
maintained in DMEM whilst HCC1806, HCC1954,
HCC1569 and DLD-1 were maintained in RPMI, both
supplemented with 10 % fetal bovine serum. SQLE in-
hibitor, NB-598, was available from MedChemexpress
(USA).
For GI50 analysis, cells were plated in 96-well plates
(1000 cells/well) and, 24 h later, NB-598 was added at a
range of concentrations from 1 nM to 10 μM. The 96-
well plates were then placed under normoxia or hypoxia
for 72 h for the colorectal cancer cell lines (HCT116
and DLD-1) or 120 h for the breast cancer cell lines
(HCC1954, HCC1569, MDA-MB-453, HCC1806 and
MDA-MB-231). Cell viability at the start of treatment or
at the endpoint was assessed using CyQuant (C7026,
Life Technologies, UK) according to the manufacturer’s
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instructions. GI50 was calculated using PRISM (Graph-
Pad, USA).
For clonogenic analysis, cells were plated in 100-mm
dishes at 1000 cells/dish and 8 h later, once cells were
attached, NB-598 was added at a concentration of 30
nM. Treated and untreated plates were incubated in
normoxia or hypoxia for 72 h. After 72 h, cell culture
medium was replaced with fresh medium followed by in-
cubation in normoxia for 7–14 days until colonies were
clear. The medium was removed and replaced with
0.5 % methylene blue dissolved in 50 % ethanol. Plates
were incubated for 1 h at room temperature before wash-
ing in tap water. Colonies were visualised and counted
utilising the GelCount™ system (Oxford Optronix, UK).
Quantitative PCR
mRNA was extracted with Trizol (Invitrogen, CA, USA)
according to the manufacturer’s instructions. DNA was
extracted using DNAzol (Invitrogen, CA, USA) according
to thr manufacturer’s instruction. Quantitative PCR was
carried out as described previously [56] utilising the
Applied Biosystems 7900HT Real-Time PCR System.
Expression of genes was normalised against the expression
of the control genes RPL11 and β-Actin. The primer
sequences for mRNA analysis were: CA9 forward,
CTTGGAAGAAATCGCTGAGG; CA9 reverse, TGGAA
GTAGCGGCTGAAGTC; SQLE forward, AAACGGGAG
GCCTCTAAATC; SQLE reverse, AGATGGCCTCGGAC
TCAAG; RPL11 forward, CTTTGGCATCCGGAGAAAT;
RPL11 reverse, TCCAGATTTCTTCTGCCTTG; β-Actin
forward, CCAACCGCGAGAAGATGA; β-Actin reverse,
CCAGAGGCGTACAGGGATAC; PYCRL forward GACA
GGAACCTATGTCACTTTCAA; PYCRL reverse, TGGC
AAAGATGACGAGCA; TSTA3 forward, GAAGATGAG
GTCTCCATCAAGG; TSTA3 reverse, CCCATCCGACT
TGGTTGTAT; CYC1 forward, CTTCGCGGGGTAGTG
TTG; CYC1 reverse TTCGACGACAAGGCCACT; SLC3
9A4 forward, CCTCTTCCTGCTGCACAAC; SLC39A4
reverse, CATCCTCGTACAGGGACAGC. As chromo-
some 8, on which SQLE and MYC are located, is highly
aberrant in breast cancer, control primers were designed
from alternative chromosome regions for DNA copy
number analysis. We identified regions which generally
represented the genome ploidy of patient/cell line DNA.
These were 2q11.1 (TEKT4) and 14q11.2 (POTEG). The
primer sequences for DNA analysis were: SQLE forward,
GCGTGCGACGGTTACTCT; SQLE reverse, GCTTCCT
CACCAGCATCC; MYC forward, CGGTTTTCGGGGCT
TTAT; MYC reverse, GGCTCTTCCACCCTAGCC; PYC
RL forward, GGCACCACCATCTATGGACT; PYCRL
reverse, CCTACTTTCTGCTGAGCTCCTT; TSTA3 for-
ward, AGCTGGAAGACAGGATCAGG; TSTA3 reverse,
AGAGCGGATGGAATGCAG; POTEG forward, GCGAT
CTGCTGGCTACTACC; POTEG reverse, CCAAATGGC
TTCTTCACAGAG; TEKT4 forward, GCTGACCACACA
CAGTCCTC; TEKT4 reverse, GGGCCCACGTCGTCTTT.
Western blots
Cell lysates were separated on 10 % SDS-PAGE and
transferred to a PVDF membrane. Primary antibodies
were used at 1:1000 unless otherwise stated. Antibodies
against CA9 (gift from J. Pastorek, Institute of Virology,
Slovak Republic), HIF1 (BD Biosciences, USA), β-Actin
(A3854, Sigma, UK), SQLE (12544-1-AP, Proteintech,
USA), MYC (9402, Cell Signalling, USA), TSTA3
(HPA023301, Sigma, UK) and PYCRL (H00065263-M01)
were utilised. Appropriate secondary horseradish
peroxidase-linked antibodies were used (Dako, UK). Im-
munoreactivity was detected with chemiluminescence
(Amersham, UK) and visualised using Image Quant
LS4000 mini (GE Healthcare, UK).
Visualisation
All visualisations were prepared in the R statistical envir-
onment (v3.0.1).
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are available through Zenodo with doi: 10.5281/zenodo.51787 (https://
zenodo.org/record/51787).
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